Market closedNon-fractional
Akebia Therapeutics/AKBA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Akebia Therapeutics
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Ticker
AKBA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
167
Website
www.akebia.com
AKBA Metrics
BasicAdvanced
$198M
Market cap
-
P/E ratio
-$0.23
EPS
0.79
Beta
-
Dividend rate
Price and volume
Market cap
$198M
Beta
0.79
Financial strength
Current ratio
1.699
Quick ratio
1.031
Long term debt to equity
-334.87
Total debt to equity
-360.789
Interest coverage (TTM)
-4.83%
Management effectiveness
Return on assets (TTM)
-8.37%
Return on equity (TTM)
206.84%
Valuation
Price to revenue (TTM)
0.973
Price to book
-7.26
Price to tangible book (TTM)
-1.75
Price to free cash flow (TTM)
-7.208
Growth
Revenue change (TTM)
-30.88%
Earnings per share change (TTM)
-29.18%
3-year revenue growth
-10.27%
3-year earnings per share growth
-56.27%
What the Analysts think about AKBA
Analyst Ratings
Majority rating from 3 analysts.
AKBA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$33M
-41.89%
Net income
-$18M
-3,083.33%
Profit margin
-54.90%
-5,279.25%
AKBA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.06
-$0.08
-
-$0.09
-
Expected
-$0.03
-$0.09
-$0.04
-$0.08
-$0.05
Surprise
140.00%
-5.88%
-
17.39%
-
AKBA News
AllArticlesVideos
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewsWire·5 days ago
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
PRNewsWire·1 week ago
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
PRNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Akebia Therapeutics stock?
Akebia Therapeutics (AKBA) has a market cap of $198M as of July 06, 2024.
What is the P/E ratio for Akebia Therapeutics stock?
The price to earnings (P/E) ratio for Akebia Therapeutics (AKBA) stock is 0 as of July 06, 2024.
Does Akebia Therapeutics stock pay dividends?
No, Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Akebia Therapeutics dividend payment date?
Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders.
What is the beta indicator for Akebia Therapeutics?
Akebia Therapeutics (AKBA) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Akebia Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.